Investigational ultra-long-acting insulin degludec reduces hypoglycaemia and improves long-term control

Novo NordiskUltra-long-acting insulin degludec, under development by Novo Nordisk, lowers blood glucose levels with significantly reduced rates of hypoglycaemia (low blood sugar) compared to insulin glargine, according to data presented at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego. Data were from two, phase three, 52-week clinical trials, one with individuals with type 1 and one in individuals with type 2 diabetes.(1,2)

Separately, in a late-breaking presentation, data revealed that insulin degludec could be dosed at different times from day to day in a 26-week trial.(3)

"Episodes of low blood sugar, known as hypoglycaemia, are a major concern for many people with diabetes," said Alan Garber, MD, Professor, Departments of Medicine, Baylor College of Medicine, in Houston, Texas, USA. "It is particularly encouraging that insulin degludec significantly reduces the rate of overall hypoglycaemia in type 2 patients and nocturnal hypoglycaemia, in patients with type 1 or type 2 diabetes. The findings of these studies suggest that insulin degludec potentially offers substantial benefits for patients and the management of their diabetes."

Findings include:

  • The 52-week studies were designed to reach similar glycaemic targets for all patients (known as treat-to-target) and at one year patients taking insulin degludec experienced * HbA1C reductions of 0.4% in patients with type 1 diabetes and 1.2% for patients with type 2 diabetes, which was statistically non-inferior to insulin glargine.(1,2)
  • In type 2 patients, a significantly lower rate of hypoglycaemic events with insulin degludec compared to those given insulin glargine (11.1 vs. 13.6 episodes/patient-yr; p=0.0359)(1)
  • Rates of nocturnal hypoglycaemia, classified as occurring between midnight and 5:59 am, were 25% lower in both the type 1 and type 2 diabetes patients taking insulin degludec than those taking insulin glargine (4.4 vs. 5.9 episodes/patient-yr, p = 0.021; and 1.4 vs. 1.8 episodes/patient-yr, p=0.0399, respectively).(1,2)

Also during ADA, data were presented showing possibility to dose insulin degludec at different times from day to day in patients with type 2 diabetes. The study demonstrated that changes in the injection time of insulin degludec from day to day (up to 40 hours apart) did not affect overall glycaemic control or risk of hypoglycaemia when compared to insulin glargine.

Insulin degludec was dosed once daily by alternating morning and evening injections from day to day while insulin glargine was administered at the same time each day, according to its prescribing instructions.(3) Insulin degludec and insulin glargine reduced HbA1C by 1.28 and 1.26 percentage points, respectively.

The trials were 'treat-to-target' studies, meaning insulin was titrated systematically to achieve a target fasting glucose level. Patients in the open-label trials, using insulin degludec and insulin glargine had similar starting glucose levels, allowing researchers to closely determine the differences between the treatments.(4)

1. Garber A. Insulin degludec improves long-term glycaemic control with less nocturnal hypoglycaemia compared with insulin glargine: 1-year results from randomized basal-bolus trial in people with type 2 diabetes. Abstract presented at the 71st Scientific Sessions of the American Diabetes Association, 26 June 2011. (NN1250-3582)
2. Heller S. Insulin degludec improves long-term glycaemic control with less nocturnal hypoglycaemia compared with insulin glargine: 1-year results from randomized basal-bolus trial in people with type 1 diabetes. Abstract presented at the 71st Scientific Sessions of the American Diabetes Association, 26 June 2011. (NN1250-3583)
3. Meneghini L. Flexible Once-daily Dosing of Insulin Degludec does not Compromise Glycemic Control or Safety Compared to Insulin Glargine Given Once Daily at the Same Time Each Day in People with Type 2 Diabetes. Abstract presented at the 71st Scientific Sessions of the American Diabetes Association, 26 June 2011. (NN1250-3668)
4. Guidance for Industry Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention; U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); February 2008 Clinical/Medical = DRAFT GUIDANCE http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071625.pdf

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...

Researchers identify chemical compound that inhibi…

An organic chemical compound shows effective antiviral activity against Ebola virus and several other viruses, according to a study led by Georgia State University. The r...

When drugs are wrong, skipped or make you sick: Th…

Rising drug prices have gotten a lot of attention lately, but the actual cost of prescription medications is more than just the dollars and cents on the bill. Researchers...

New class of drugs could help tackle treatment-res…

Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies. The drug may not become availa...

Researchers propose key elements of antimicrobial …

Antimicrobial stewardship programs (ASPs) in hospitals play a vital role in managing the threat of antibiotic resistance. To be of maximum effectiveness, essential elemen...